Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Breaking from AHA25
The phase 3 CORALreef HeFH trial brings a major step forward: the first oral PCSK9 inhibitor, enlicitide, cuts LDL-C by ≈60% vs placebo in adults with heterozygous familial hypercholesterolemia already on maximally tolerated statins.
- LDL-C ↓58% at 24 weeks and sustained −55% at 52 weeks
- ApoB ↓48%, non-HDL-C ↓52%, Lp(a) ↓25%
- >70% reached LDL < 70 mg/dL, with excellent tolerability
- No excess in adverse events vs placebo
Enlicitide (oral PCSK9 inhibitor, 20 mg QD) shows efficacy comparable to injectable antibodies — potentially transforming lipid management for HeFH and beyond. doi:10.1001/jama.2025.20620”
Read the full article here.
Article: Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia
Authors: Christie M. Ballantyne, Laura Gellis, Jean-Claude Tardif, Puja Banka, Ann Marie Navar, Emil Andreas Asprusten, Russell Scott, Erik S. G. Stroes, Samar Froman, Geraldine Mendizabal, Fan Wang, Alberico L. Catapano
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 6, 2026, 04:46Ursula Porage Dona: Bringing the Bleeding Disorders Community Together at WFH 2026 with NNHF
-
Apr 6, 2026, 04:17Arun V J: How War Reshaped Blood Transfusion
-
Apr 6, 2026, 03:57Isabella Cieri: How TEG Is Transforming Vascular Surgery Care
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination
-
Apr 5, 2026, 18:05Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease
-
Apr 5, 2026, 17:45Matthew Walls: Recognising CAD PRS as a New ‘Risk Enhancing Factor’ in the 2026 ACC/AHA Guidelines
-
Apr 5, 2026, 17:44Philip A. Chan: Occasional Heavy Drinking Leads to 3 Times Higher Liver Fibrosis Risk in MASLD
-
Apr 5, 2026, 17:42Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia